Executives at Moderna, which made one of the two vaccines approved for use in the U.S., sold $321 million of their stock in more than 700 transactions. At Merck, executives sold $58 million of their shares and at Novarax they sold $40 million of their shares.
For comparison, executives at the same 13 companies sold 4.7 million shares worth $132 million in 2019, according to Kaleidoscope, a research consulting firm.
Experts in corporate compensation say these sales are permitted as long as they adhere to insider trader rules and represent a shift to combine company stock with executive compensation to tie pay and performance, reports WSJ.
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
